ArticleBMC infectious diseases2026
Performance evaluation of TaqMan Array Card real-time PCR for multi-pathogen detection in acute undifferentiated febrile illness.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute undifferentiated febrile illness (AUFI) is a leading cause of morbidity and mortality worldwide, particularly in tropical and subtropical regions. The causative pathogen is often unidentified due to the wide range of potential etiologies and non-specific clinical features. A diagnostic approach capable of detecting multiple pathogens simultaneously could improve clinical management and support disease surveillance efforts.
methodsWe evaluated a real-time PCR–based TaqMan Array Card (TAC) for detecting 21 AUFI-associated pathogens, comprising eight viruses, one parasite, and twelve bacteria. Analytical performance was assessed using DNA control plasmids and extracted or synthesized nucleic acids from reference strains to determine the limit of detection (LOD), cross-reactivity, intra- and inter-assay reproducibility. Clinical performance was evaluated with 185 archived clinical samples and compared against pathogen-specific real-time PCR assays.
resultsThe TAC assay detected all 21 AUFI pathogen, with LODs ranging from 10 to 100 copies/µL for plasmid controls and 2 to 2,000 copies/µL for extracted nucleic acids. Based on clinical specimens, the overall accuracy, sensitivity, and specificity for detecting pathogens causing AUFI were 92.97% (95% CI, 88.28–96.21%), 96.43% (95% CI, 91.11–99.02%), and 87.67% (95% CI, 77.88–94.20%), respectively. After Ct cut-off optimization, the accuracy increased to 95.14% (95% CI, 90.97–97.75%) and the specificity to 93.15% (95% CI, 84.74–97.74%).
conclusionsThe AUFI-customized TAC demonstrated satisfactory analytical and clinical performance for simultaneous multi-pathogen detection, with improved accuracy using pathogen-specific Ct cut-offs. The assay shows potential utility for diagnostic support and surveillance of acute febrile illness in Thailand and Southeast Asia. However, limited low-titer clinical samples and sporadic late amplification for certain bacterial targets warrant confirmatory testing and further prospective validation before broader implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.